SCHEMBL31197222

SCHEMBL31197222

O=C(O)c1ccc(F)c(OCc2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 1/20 0.71
MRGPRX4 Q96LA9 7/20 0.69
NR4A2 P43354 2/20 0.57
NR4A1 P22736 1/20 0.57
NR4A3 Q92570 1/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
RXRA P19793 5/20 0.54
RXRB P28702 4/20 0.54
RXRG P48443 3/20 0.54
HPGD P15428 2/20 0.54
NPC1 O15118 1/20 0.54
MITF O75030 1/20 0.54
TP53 P04637 1/20 0.54
XBP1 P17861 1/20 0.54
NFKB1 P19838 1/20 0.54
RAB9A P51151 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5605127 1.00 PTGER1 (0.71) PTGER1MRGPRX4NR4A2NR4A1NR4A3
SCHEMBL229472 0.88 MRGPRX4 (0.69) PTGER1MRGPRX4NR4A2NR4A1NR4A3
SCHEMBL3159761 0.87 KMT2A (0.57) PTGER1MRGPRX4KMT2AHPGDNPC1
SCHEMBL3721195 0.85 HPGD (0.58) PTGER1MRGPRX4MEN1KMT2ARXRA
SCHEMBL29556736 0.85 MRGPRX4 (0.62) PTGER1MRGPRX4NR4A2NR4A1NR4A3
SCHEMBL1600077 0.85 MRGPRX4 (0.62) PTGER1MRGPRX4NR4A2NR4A1NR4A3
SCHEMBL6845399 0.85 MRGPRX4 (0.55) PTGER1MRGPRX4
Hydrochloric Acid SCHEMBL10857748 0.84 MRGPRX4 (0.61) PTGER1MRGPRX4NR4A2NR4A1NR4A3
SCHEMBL5100155 0.83 PTGER1 (1.00) PTGER1MRGPRX4RXRARXRBRXRG
SCHEMBL25337360 0.83 MRGPRX4 (0.59) PTGER1MRGPRX4NR4A2NR4A1NR4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214974-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2025-07-03 US disclosed
US-12286421-B2 Inhibiting monoacylglycerol lipase (MAGL) PSY THERAPEUTICS, INC. (US) 2025-04-29 US disclosed
US-20250084065-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2025-03-13 US disclosed
US-20240308985-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2024-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214974-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LIPC PTGER1 4023/4885MRGPRX4 1186/4885NR4A2 4573/4885
US-20250084065-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LPL PTGER1 2238/4885MRGPRX4 917/4885NR4A2 2851/4885
US-12286421-B2 Inhibiting monoacylglycerol lipase (MAGL) MGLL, PNLIP, LIPC PTGER1 4023/4885MRGPRX4 1186/4885NR4A2 4573/4885
US-20240308985-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LIPC PTGER1 4023/4885MRGPRX4 1186/4885NR4A2 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.